CEFTRIAXONE FOR INJECTION POWDER FOR SOLUTION

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

CEFTRIAXONE (CEFTRIAXONE SODIUM)

可用日期:

FRESENIUS KABI CANADA LTD

ATC代码:

J01DD04

INN（国际名称）:

CEFTRIAXONE

剂量:

1G

药物剂型:

POWDER FOR SOLUTION

组成:

CEFTRIAXONE (CEFTRIAXONE SODIUM) 1G

给药途径:

INTRAMUSCULAR

每包单位数:

100

处方类型:

Prescription

治疗领域:

THIRD GENERATION CEPHALOSPORINS

產品總結:

Active ingredient group (AIG) number: 0117292007; AHFS:

授权状态:

APPROVED

授权日期:

2015-04-07

产品特点

Ceftriaxone for Injection – Product Monograph_ _Page 1 of 58
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
CEFTRIAXONE FOR INJECTION
Sterile Powder for Solution, 250 mg, 500 mg, 1 g, 2 g ceftriaxone (as
ceftriaxone sodium) per vial
Pharmacy Bulk Package 10 g ceftriaxone (as ceftriaxone sodium) per
vial
100 g ceftriaxone (as ceftriaxone sodium) in SmartPak® Pharmacy Bulk
Package
Intravenous or Intramuscular
USP
Antibiotic
FRESENIUS KABI CANADA LTD. Date of Initial Authorization:
165 Galaxy Blvd. Suite 100 DEC 16, 2006
Toronto, ON M9W 0C8 Date of Revision:
JAN 05, 2022
Submission Control No.: 255106
Ceftriaxone for Injection – Product Monograph_ _Page 2 of 58
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, General, Severe Cutaneous Adverse
Reactions
01/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................................
4
1
INDICATIONS
......................................................................................................................
4
1.1 Pediatrics
.....................................................................................................................
5
1.2 Geriatrics
.....................................................................................................................
5
2
CONTRAINDICATIONS
..........................................................................................................
5
4
DOSAGE
AND
ADMINISTRATION
...........................................................................................
5
4.1 Dosing Considerations
...................................................................................................
5
4.2 Recommended Dose and Dosage Adjustment
................................................................... 6